滙豐大幅調升復星醫藥目標價 52.2% 理由是什麼？

智通財經
2021.07.16 02:30
智通財經 APP 獲悉，滙豐研究發佈研究報告，復星醫藥 (02196) 多款新藥可帶動收入增長，同時疫苗、CAR-T 細胞治療、醫美項目可進一步帶動增長，維持 “買入” 評級，目標價由 46 港元大幅調升 52.2% 至 70 港元。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.